NCT01035983View on ClinicalTrials.gov

Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches

PHASE3CompletedINTERVENTIONAL
Enrollment

550

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Migraine
Interventions
DRUG

Frovatriptan 2.5 mg

Trial Locations (5)

Unknown

Munich

Budapest

Warsaw

Cape Town

London

Sponsors
All Listed Sponsors
collaborator

Vernalis (R&D) Ltd

INDUSTRY

lead

Endo Pharmaceuticals

INDUSTRY